Ad
Friday, 25 November 2016
French cancer specialist Innate Pharma can remain independent, for now: CEO
PARIS (Reuters) - France's Innate Pharma believes that its cash position and portfolio are sufficiently robust for the cancer drug company to remain independent for the time being and will seek co-development deals modeled on an agreement struck with AstraZeneca in April.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment